ANIK Earnings Prediction
The chart below shows how ANIK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ANIK sees a +6.57% change in stock price 10 days leading up to the earnings, and a -1.02% change 10 days following the report. On the earnings day itself, the stock moves by -5.25%. This data can give you a slight idea of what to expect for the next quarter's release.
ANIK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
38.75M
--
-7.56%
Gross Margin
62.29%
--
-4.58%
Operating Margin
-4.52%
--
-658.02%
Net Margin
-77.20%
--
36661.90%
EPS
-2.03
--
20200.00%
No Data Available
ANIK Earnings Analysis
Anika Therapeutics Inc Corporation (ANIK.O) Earnings Conference Call
Positive
Revenue Decline in Q3: Anika generated $38.8 million in total revenue in the third quarter, down $2.7 million from the same period in 2023.
Surgery Volume Surge: We grew the total number of surgeries in the third quarter by greater than 40% sequentially as we completed nearly 200 surgeries, in line with the guidance shared at the end of the second quarter.
Sequential Case Growth: Integrity performed well with over 40% sequential growth in cases, in line with our prior guidance and remains on track to be a key contributor in the fourth quarter and 2025.
Projected 2024 Growth: We expect to deliver 16% growth at the midpoint of our guidance for 2024, demonstrating our ability to deliver growth in the HA-focused products that we sell through our commercial channel.
Strong Cash Position: We ended the third quarter with $62.4 million in cash and no debt.
Negative
Revenue Decline Analysis: Anika generated $38.8 million in total revenue in the third quarter, down $2.7 million from the same period in 2023.
Revenue Decline Factors: This decline was driven by lower revenue from our JNJ Medtech partner and softness in the Arthrosurface and Sports Medicine businesses.
OA Pain Management Revenue Decline: Revenue in our largest product family, OA Pain Management, decreased 2% in the third quarter to $24.4 million, primarily due to lower U.S. sales from JNJ, which faced lower volumes and competitive pricing pressures.
Market Leadership Resilience: Despite reduced market access and lower pricing, Monovisc and Orthovisc can remain market leaders in the U.S.
Quarterly Net Loss Increase: The net loss for the quarter was $29.9 million compared to a net loss of $6.6 million in the prior year.
ANIK FAQs
How does ANIK typically perform around its earnings report dates?
Is Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ANIK Earning Call Sentiment
Anika Therapeutics, Inc. (ANIK) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ANIK.O
0.92%Positive
The earnings call reveals multiple challenges: declining revenue in key segments, a significant net loss, and reduced gross margins. Workforce reduction and market access issues add to concerns. The Q&A section highlights unclear guidance, particularly on gross margins, which raises uncertainty. Despite a share repurchase program, the overall sentiment is negative due to financial struggles and lack of strong positive catalysts.